These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1632116)

  • 21. Ovine model for clear-cut study on the role of cholecystokinin in antral, small intestinal and gallbladder motility.
    Romański KW
    Pol J Pharmacol; 2004; 56(2):247-56. PubMed ID: 15156076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noradrenergic inhibition of canine gallbladder contraction and murine pancreatic secretion during stress by corticotropin-releasing factor.
    Lenz HJ; Messmer B; Zimmerman FG
    J Clin Invest; 1992 Feb; 89(2):437-43. PubMed ID: 1737835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholecystokinin antagonists: pharmacological and therapeutic potential.
    Herranz R
    Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.
    Ellrichmann M; Ritter PR; Otte JM; Schrader H; Banasch M; Brunke G; Herzig KH; Seebeck J; Schmidt WE; Schmitz F
    Regul Pept; 2007 Mar; 139(1-3):136-40. PubMed ID: 17175037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications.
    Maselli MA; Mennuni L
    Minerva Gastroenterol Dietol; 2003 Sep; 49(3):211-6. PubMed ID: 16484960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gallbladder motility and cholecystokinin secretion in chronic pancreatitis: relationship with exocrine pancreatic function.
    Gielkens HA; Eddes EH; Vecht J; van Oostayen JA; Lamers CB; Masclee AA
    J Hepatol; 1997 Aug; 27(2):306-12. PubMed ID: 9288605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of endogenous CCK and CCK1 receptors in colonic motor function.
    Varga G; Bálint A; Burghardt B; D'Amato M
    Br J Pharmacol; 2004 Apr; 141(8):1275-84. PubMed ID: 15100163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CCK(-like) receptor in the animal kingdom: functions, evolution and structures.
    Staljanssens D; Azari EK; Christiaens O; Beaufays J; Lins L; Van Camp J; Smagghe G
    Peptides; 2011 Mar; 32(3):607-19. PubMed ID: 21167241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cholecystokinin in the regulation of gastrointestinal motility.
    Grider JR
    J Nutr; 1994 Aug; 124(8 Suppl):1334S-1339S. PubMed ID: 8064380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit.
    Degen LP; Peng F; Collet A; Rossi L; Ketterer S; Serrano Y; Larsen F; Beglinger C; Hildebrand P
    Gastroenterology; 2001 Feb; 120(2):361-8. PubMed ID: 11159876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal dysfunction in Parkinson's Disease.
    Jost WH
    J Neurol Sci; 2010 Feb; 289(1-2):69-73. PubMed ID: 19717168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives of CCK antagonists in pancreatic research. Part II. Experimental studies.
    Takács T; Pap A
    Int J Pancreatol; 1991 Sep; 10(1):1-8. PubMed ID: 1757727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gallbladder and gastric emptying: relationship to cholecystokininemia in diabetics.
    Bucceri AM; Calogero AE; Brogna A
    Eur J Intern Med; 2002 Mar; 13(2):123-128. PubMed ID: 11893470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promotility medications--now and in the future.
    Karamanolis G; Tack J
    Dig Dis; 2006; 24(3-4):297-307. PubMed ID: 16849857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists.
    Niederau C; Grendell JH
    Digestion; 1999; 60 Suppl 1():69-74. PubMed ID: 10026436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.
    Berna MJ; Tapia JA; Sancho V; Jensen RT
    Curr Opin Pharmacol; 2007 Dec; 7(6):583-92. PubMed ID: 17997137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCK antagonists: pharmacology and therapeutic interest.
    Wettstein JG; Buéno L; Junien JL
    Pharmacol Ther; 1994; 62(3):267-82. PubMed ID: 7972336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal motility in pregnancy.
    Everson GT
    Gastroenterol Clin North Am; 1992 Dec; 21(4):751-76. PubMed ID: 1478733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.